UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) December 1730, 2009

VION PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)


Delaware	000-26534	13-3671221

(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)


4 Science Park, New Haven, CT		06511

(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (203) 498-4210

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~o Soliciting material pursuant to Rule ~~1.03~~14a-12 ~~Bankruptcy~~under ~~and~~the ~~Receivership~~Exchange Act (17 CFR 240.14a-12)

Ono Pre-commencement ~~December 17,~~communications ~~2009,~~pursuant ~~Vion~~to ~~Pharmaceuticals, Inc.~~ Rule 14d-2(~~the “Debtor” or the “Company”~~b) ~~filed a voluntary petition (the “Chapter 11 Petition”) for relief~~ under ~~Chapter 11 of Title 11 of~~ the ~~United~~Exchange ~~States Bankruptcy~~Act ~~Code~~ (~~the~~17 ~~“Bankruptcy Code”) in the United States Bankruptcy Court for the District of~~CFR ~~Delaware~~ 240.14d-2(~~the “Bankruptcy Court”~~b).)

~~Under~~o Pre-commencement ~~Chapter 11,~~communications ~~certain~~pursuant ~~claims in existence prior~~ to ~~the~~Rule 13e-4(c) ~~Debtor’s filing of the petition for relief~~ under the ~~Bankruptcy~~Exchange ~~Code~~Act ~~are~~(17 ~~stayed while the Debtor continues business operations as a~~CFR ~~debtor-in-possession~~240. ~~The Debtor will continue to operate its business as debtor~~13e-~~in-possession~~4(c)) ~~under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code.~~

~~A copy of the press release dated December~~Item ~~17, 2009, announcing the bankruptcy filing is attached hereto as Exhibit 99~~8.101 ~~and~~Other ~~is incorporated herein by reference~~Events.

~~Item~~ On December 230, 2009, Vion Pharmaceuticals, Inc.04 ~~Triggering~~(the ~~Events~~“Company”) ~~That~~announced ~~Accelerate~~that orthe ~~Increase~~U.S. aFood and ~~Direct~~Drug ~~Financial~~Administration ~~Obligation~~(“FDA”) orhad anresponded to its Special Protocol Assessment (“SPA”) request to ~~Obligation~~evaluate ~~under~~the anPhase III ~~Off~~randomized trial HOVON AML 92 sponsored by the Dutch-~~Balance~~Belgian ~~Sheet~~Cooperative Group ~~Arrangement~~for Hematology Oncology (“HOVON”) of its lead product Onrigin™. The FDA raised concerns with the HOVON trial design and requested modifications that would require a new Phase III trial at significant additional time and expense.

The ~~Chapter 11~~Company ~~bankruptcy~~will ~~filing~~evaluate ~~described~~whether into ~~Item 1.03~~file ~~above~~another ~~constitutes~~SPA for an ~~event~~alternative ofrandomized ~~default under~~Phase III ~~the~~trial ~~Company’s~~within ~~indenture~~the ~~with~~next Utwo weeks.S. ~~Bank~~In ~~National~~this ~~Association~~context, ~~dated~~the ~~February 20,~~SPA ~~2007~~process ~~(the “Indenture”)~~is ~~relating~~intended to ~~the~~evaluate ~~Company’s~~a ~~$60,000,000~~Phase III protocol ~~7.75%~~whose ~~Convertible~~data ~~Senior~~will ~~Notes~~form (the ~~“Notes”).~~primary ~~On December 17,~~basis ~~2009,~~for ~~all~~an ~~unpaid~~efficacy ~~principal~~claim. ~~of,~~The ~~and~~Phase III ~~accrued~~randomized trial ~~and~~in ~~unpaid~~acute ~~interest~~myeloid ~~and~~leukemia ~~additional interest,~~(“AML”) ifis ~~any,~~in onresponse to the ~~Notes~~FDA’s ~~then~~complete ~~outstanding~~response ~~became~~letter ~~automatically~~to ~~due and payable. However,~~ the ~~ability~~Company’s ofNew ~~the~~Drug ~~holders~~Application offor ~~the~~Onrigin™ ~~Notes~~requiring tothat ~~seek~~a ~~remedies~~randomized totrial ~~enforce~~be ~~their~~conducted ~~rights~~to support ~~under~~ the ~~Indenture~~approval ~~is automatically~~of ~~stayed~~Onrigin™ asfor ~~a result of~~ the ~~filing~~treatment of ~~the Chapter 11 petition~~AML.

A copy of the press release announcing the response to the SPA is attached as Exhibit 99.1 hereto and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

EXHIBIT NO.		DESCRIPTION		~~DESCRIPTION~~
99.1	~~99.1~~	Press release dated December 30, 2009		~~Press release dated December 17, 2009~~

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VION PHARMACEUTICALS, INC.
Date: December 17, 2009	By:	/s/ Howard B. Johnson
Date: December 31, 2009	By:	/s/ Howard B. Johnson
		Name:	Howard B. Johnson
		Title:	President and Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO.		DESCRIPTION		~~DESCRIPTION~~
99.1	~~99.1~~	Press release dated December 30, 2009		~~Press release dated December 17, 2009~~

Filing Compare · VION PHARMACEUTICALS INC